Pharma BD Deal Intelligence
The combined entity will be a GI-focused powerhouse with 22 marketed products, pro-forma revenues of $1.348B and adjusted EBITDA of $537M.
Execution risk centers on marketing Glumetza and Ruconest outside the core GI call point; integration of Santarus's primary-care reps will be the swing factor.
A value-creating deal that diversifies Salix's revenue base; Uceris alone with $400-700M peak potential could justify approximately two-thirds of the purchase…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Salix acquired Santarus at $32/share cash (~$2.6B; 36% premium); expanded Salix's GI portfolio and added primary care/diabetes assets; financed via $800M cash + $1.95B Jefferies committed debt.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Salix Pharmaceuticals / Santarus Inc. (this deal) | 2013 | $2.6B | 29 |
| Salix Pharmaceuticals / Oceana Therapeutics, Inc. | 2011 | $300M | 29 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Biogen Idec Inc. / Elan Corporation plc (Tysabri rights) | 2013 | $3.2B | 77 |
← Browse all deals · How we score deals
More: 2013 deals · Gastroenterology deals